InMed Pharmaceuticals’ INM-901 Shows Promise in Preclinical Alzheimer’s Study

InMed Pharmaceuticals Inc. (NASDAQ: INM) has announced promising preclinical results for its investigational drug, INM-901, as a potential treatment for Alzheimer’s disease. The study highlights significant reductions in markers of neuroinflammation and neuronal damage, reinforcing the drug’s potential to address key pathological processes in Alzheimer’s disease.

Key Findings

1. Reduction in Neuroinflammation:

INM-901 demonstrated a dose-dependent and statistically significant decrease in pro-inflammatory cytokines, including TNF-α, IL-1β, and INF-γ, associated with disease progression in Alzheimer’s.

2. Neurodegeneration Marker Improvement:

The study showed a significant reduction in neurofilament light chain (NfL) levels in plasma. Elevated NfL levels are a biomarker for neuronal injury, and their reduction indicates potential neuroprotective effects.

3. Gene Expression Modulation:

INM-901 reduced the expression of key neuroinflammatory genes, such as GFAP, CD-33, and TLR-2, in the brain. These changes suggest the drug’s ability to mitigate neuroinflammatory responses associated with Alzheimer’s disease.

The Mechanism Behind INM-901

INM-901 operates through a dual mechanism aimed at reducing neuroinflammation and protecting neuronal integrity:

• Anti-inflammatory Action:

The drug targets inflammatory signalling pathways, suppressing the release of cytokines that drive chronic neuroinflammation. By downregulating these pathways, INM-901 helps create a more neuroprotective environment in the brain.

• Regulation of Glial Cell Activity:

INM-901 modulates the activity of glial cells, such as microglia and astrocytes, which play a central role in neuroinflammation. Overactivation of these cells contributes to neuronal damage, but the drug’s action helps to restore their normal function.

Dr. Eric Hsu, Senior Vice President of Preclinical Research and Development at InMed, stated, “The results of this long-term preclinical study are highly encouraging, as they align with our short-term proof-of-concept findings. INM-901’s ability to reduce inflammation and protect neurons highlights its potential as a therapeutic option for Alzheimer’s.”

These findings support INM-901’s therapeutic potential and provide a foundation for future clinical trials. The mechanism of action, focusing on inflammation and neuronal health, aligns with growing evidence that addressing neuroinflammation is critical for slowing Alzheimer’s progression.

Next Steps

With these preclinical results, InMed Pharmaceuticals is advancing towards clinical trials to evaluate INM-901’s safety and efficacy in humans. If successful, this drug could represent a novel approach to tackling Alzheimer’s by simultaneously targeting inflammation and neuronal protection.

Additional Information: INM-901 for Alzheimer’s disease